Shares of REGENXBIO Inc. (RGNX) are gaining about 11 percent on Monday morning after the company announced alignment with the U.S. Food and Drug Administration regarding the next steps needed for a potential accelerated approval of NAVSUNLI for the treatment of Hunter syndrome.
The company's shares are currently trading at $8.67 on the Nasdaq, gaining 11.58 percent in the latest session. The stock opened at $8.50 and touched an intraday high of $9.12. Over the past 12 months, the shares have traded between $5.45 and $16.19.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.